AXT-1003

DRUG2 trials

Sponsors

Axter Therapeutics (Beijing) Co., Ltd

Conditions

Advanced Solid TumorNon-Hodgkin LymphomaRelapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

TerminatedNCT05965505

Axter Therapeutics (Beijing) Co., LtdRelapsed or Refractory Non-Hodgkin's Lymphoma

Start: 2023-08-11End: 2023-09-05Updated: 2024-08-01

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

RecruitingNCT06484985

Axter Therapeutics (Beijing) Co., LtdAdvanced Solid Tumor, Non-Hodgkin Lymphoma

Start: 2024-09-04End: 2027-09-01Target: 78Updated: 2026-01-28